Charmacy Pharmaceutical Co Ltd
HKEX:2289
P/B
Price to Book Value
Price to Book Value (P/B) ratio is a valuation multiple that measures the market's valuation of a company relative to its book value. The P/B ratio is only considered useful in practice when applied to capital-intensive businesses.
Market Cap | P/B | ||||
---|---|---|---|---|---|
CN |
C
|
Charmacy Pharmaceutical Co Ltd
HKEX:2289
|
1.5B HKD | 2.4 | |
US |
Mckesson Corp
NYSE:MCK
|
72.5B USD | -36.7 | ||
US |
Cencora Inc
NYSE:COR
|
44.1B USD | 40.7 | ||
US |
Amerisourcebergen Corp
NYSE:ABC
|
35.4B USD | 51.5 | ||
US |
Cardinal Health Inc
NYSE:CAH
|
23.6B USD | -7.2 | ||
US |
Henry Schein Inc
NASDAQ:HSIC
|
9.4B USD | 2.6 | ||
KR |
C
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | 6 | |
CN |
Sinopharm Group Co Ltd
HKEX:1099
|
66.9B HKD | 0.9 | ||
IT |
Amplifon SpA
MIL:AMP
|
7.5B EUR | 6.6 | ||
CN |
Huadong Medicine Co Ltd
SZSE:000963
|
57.5B CNY | 2.7 | ||
CN |
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
52B CNY | 0.8 |
P/B Forward Multiples
Forward P/B multiple is a version of the P/B ratio that uses forecasted equity for the P/B calculation. 1-Year, 2-Years, and 3-Years forwards use equity forecasts for 1, 2, and 3 years ahead, respectively.